TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?

Immunotherapy. 2013 Aug;5(8):791-4. doi: 10.2217/imt.13.82.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Blocking / therapeutic use*
  • Clinical Trials as Topic
  • Drug Resistance
  • Drug-Related Side Effects and Adverse Reactions / immunology
  • Drug-Related Side Effects and Adverse Reactions / prevention & control*
  • Humans
  • Immunotherapy / methods*
  • Interferons / antagonists & inhibitors
  • Lenalidomide
  • Lupus Erythematosus, Cutaneous / immunology
  • Lupus Erythematosus, Cutaneous / therapy*
  • Thalidomide / analogs & derivatives
  • Thalidomide / pharmacology
  • Thalidomide / therapeutic use
  • Tumor Necrosis Factor-alpha* / immunology

Substances

  • Antibodies, Blocking
  • Tumor Necrosis Factor-alpha
  • Thalidomide
  • Interferons
  • Lenalidomide